go to contents

BlueSky Immunotherapies GmbH

Back to list

Facts

Founded
2014
Staff
12
Organization type
RDM biotech/pharma
Region
Vienna
Cluster
LISAvienna
Focus
human health / animal health

Profile

BlueSky Immunotherapies GmbH (Ltd.) is a clinical-stage biotech company. The company’s business is based on its own proprietary, novel technology platform for interferon-inducing viral vectors (delNS). Interferons have immunostimulatory and antiviral properties. BlueSky uses these delNS- mediated properties for therapies against cancer and viral infectious diseases.

R&D:Preclinical studies have proven that the immunostimulatory properties of the delNS-vector “delNS/E6E7” destroy tumours. The vector’s potential for fighting metastases has also been demonstrated in animal models. Moreover, we have shown that delNS/E6E7 eliminates aggressive and incurable papilloma virus induced tumours in horses. Based on these promising results, BlueSky is currently conducting a phase I clinical trial with delNS/E6E7 for prevention of cervical carcinoma in humans.

Similar companies in RDM biotech/pharma

Angothera GmbH

Organization type
RDM biotech/pharma
Region
Lower Austria
Cluster
ecoplus
Focus
human health / animal health
Details

EveliQure Biotechnologies GmbH

Organization type
RDM biotech/pharma
Region
Vienna
Cluster
LISAvienna
Focus
human health
Details

RIANA Therapeutics GmbH

Organization type
RDM biotech/pharma
Region
Vienna
Cluster
LISAvienna
Focus
human health
Details

EDERA SAFETY GmbH

Organization type
RDM biotech/pharma
Region
Styria
Details

Contact

Mariahilfer Straße 101/1/21
1060 Wien
Vienna

Contact:
Email: office@blueskyvaccines.com
Website